Motley Fool Asset Management LLC Buys 171,150 Shares of DexCom, Inc. (NASDAQ:DXCM)

Motley Fool Asset Management LLC increased its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 168.7% in the third quarter, HoldingsChannel reports. The firm owned 272,622 shares of the medical device company’s stock after buying an additional 171,150 shares during the period. DexCom makes up 1.1% of Motley Fool Asset Management LLC’s portfolio, making the stock its 22nd largest position. Motley Fool Asset Management LLC’s holdings in DexCom were worth $17,993,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of DXCM. Migdal Insurance & Financial Holdings Ltd. bought a new position in DexCom during the second quarter worth about $25,000. Sachetta LLC lifted its position in DexCom by 255.2% during the second quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock worth $27,000 after acquiring an additional 171 shares during the last quarter. Riverview Trust Co lifted its position in DexCom by 100.4% during the third quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock worth $31,000 after acquiring an additional 232 shares during the last quarter. DT Investment Partners LLC lifted its position in DexCom by 492.2% during the second quarter. DT Investment Partners LLC now owns 379 shares of the medical device company’s stock worth $43,000 after acquiring an additional 315 shares during the last quarter. Finally, RPg Family Wealth Advisory LLC acquired a new stake in DexCom during the third quarter worth approximately $57,000. Institutional investors own 97.75% of the company’s stock.

DexCom Stock Performance

NASDAQ DXCM opened at $80.91 on Wednesday. The firm’s fifty day moving average price is $71.83 and its two-hundred day moving average price is $86.83. The stock has a market cap of $31.60 billion, a PE ratio of 48.45, a PEG ratio of 2.43 and a beta of 1.12. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46.

Insiders Place Their Bets

In related news, COO Jacob Steven Leach sold 746 shares of the business’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the sale, the chief operating officer now owns 264,915 shares of the company’s stock, valued at $18,318,872.25. The trade was a 0.28 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Sadie Stern sold 4,259 shares of the business’s stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total transaction of $318,275.07. Following the completion of the sale, the executive vice president now directly owns 71,192 shares in the company, valued at approximately $5,320,178.16. This represents a 5.64 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 5,431 shares of company stock valued at $399,319. 0.30% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several brokerages have issued reports on DXCM. Oppenheimer cut their price objective on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. StockNews.com downgraded shares of DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. Sanford C. Bernstein raised their price objective on shares of DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a research report on Friday, October 25th. Piper Sandler reiterated an “overweight” rating and issued a $90.00 price target on shares of DexCom in a research report on Monday, August 26th. Finally, Royal Bank of Canada dropped their price target on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Seven investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, DexCom currently has a consensus rating of “Moderate Buy” and an average target price of $104.59.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.